Torrent Pharma gets USFDA EIR for Indrad facility
Ahmedabad: Torrent Pharma has informed in a BSE filing that the U.S. Food and Drug Administration (USFDA) has issued Establishment Inspection Report (“EIR”) with Voluntary Action Indicated (“VAI”) classification for the manufacturing facility at Indrad, Gujarat. The inspection has now been successfully closed by the USFDA.
VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action
The USFDA had conducted inspection at the facility from 03-Jun-24 to 12-Jun-24 and issued five observations.
Read also: Torrent Pharma gets 5 USFDA observations for Indrad facility
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).
Read also: Torrent Pharma is said to seek raising USD 3 billion for KKR stake in JB Chemicals: Report
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.